|
Interview
"Physicians have always been one of our main focuses"
Having almost 20 years of experience in the pharmaceutical industry, Fabio Salata has already worked in companies like Pharmacia USA and AstraZeneca of Brazil, taking over marketing and sales positions. At the moment he is the marketing and demand director of the Italian Chiesi pharmaceuticals.
During an exclusive interview to Top Team, the executive, post-graduated in marketing from ESPM, assesses the current situation of Chiesi in Brazil, talks about investments and says that the Respiratory Line will keep on being the main business of Chiesi.
The executive also comments about the work done by the company with physicians: "besides our sales team who regularly carry out medical detailing work, the company has already been present in medical and patients´ associations".
Check the main parts of the interview:
Is the action of Chiesi in Brazil strategic?
Absolutely. From the historical point of view, Chiesi of Brazil, also known as Farmalab, was the first foreign branch in the Italian group Chiesi Farmaceuticci. Nowadays, Chiesi owns branches in 24 countries. Brazil is ranked sixth when it comes to revenue and it is part of our priority for emerging countries like China, Russia and Turkey.
Last year, the company celebrated its 35th anniversary in Brazil. Which were the most remarkable moments of the company?
Chiesi focuses on respiratory line. One of the most remarkable moments for Chiesi was to bring to Brazil in the 90´s the surfactant Curosurf for premature infants. Another remarkable moment was the launch of Clenil, beclometason, for asthma treatment. Over the last years, thousands of patients, both in the public and private healthcare systems were benefitted with such product.
Does the current moment of the European economy demand precaution when it comes to the launch of new drugs?
Due to negative moments that European countries have faced, I see that there is a great expectation for aggressive growth in emerging countries, just like here in Brazil. As a multinational company, it is a great opportunity for us to establish our position as a major country in the corporation business.
In which areas will Chiesi invest in Brazil? Will there be new launches?
The Respiratory Line will keep on being our main business. Our newest launch was the Fostair, beclomethasone and phormoterol, for the treatment of asthma. It is a state-of-the-art product patented by Chiesi, which has unique benefits for patients.
To wrap up, which work does Chiesi do with physicians?
Throughout Chiesi history, physicians have always been one of our main focuses. Besides our sales team who regularly carry out medical detailing work, the company has already been present in medical and patients´ associations by continuously working to offer a better access to the whole society.
|
Print this page
Mail this page